BRIEF—Neurogene raises $68.5 million in series A round

New York-based Neurogene, a specialist in rare neurological diseases, has raised $68.5 million in a series A financing round led by Samsara BioCapital, EcorR1 Capital, Cormorant Asset Management and others.

Neurogene is focused on cell and gene therapies addressing unmet medical needs.

The firm will use the money to “advance multiple gene therapy programs into IND-enabling studies and clinical trials for patients with rare neurological diseases, invest in novel technologies for indications not addressed by traditional gene therapy approaches and establish a viral vector manufacturing facility.”